Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership

Ownership Summary

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is held by 164 institutional investors per 13F filings through March 2026.

• Collectively, these holders controlled 874681.7% of Corvus Pharmaceuticals's outstanding shares in March 2026, up from 681737.6% in December 2025.
• Their total shares held in CRVS increased 76.94% from the prior quarter, while the number of investors in Corvus Pharmaceuticals increased 84.27% year over year.
• Activity in CRVS broke down as 124 buyers, 30 sellers, and 10 unchanged among 164 total holders.
• Institutional investors collectively held 69.97Mn shares in Corvus Pharmaceuticals as of March 2026, up by 30.43Mn shares quarter on quarter, and up 29.19Mn shares year over year.
• As of March 31, 2026, the biggest holder of Corvus Pharmaceuticals is ORBIMED ADVISORS LLC at 7.17Mn shares, representing 89562.58% of shares outstanding.
• Leading buyers of Corvus Pharmaceuticals shares for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (3.23Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.92Mn), Deep Track Capital, LP (2.49Mn), Commodore Capital LP (2.26Mn), WELLINGTON MANAGEMENT GROUP LLP (2.0Mn).
• Top sellers of CRVS stock for the quarter ending March 2026 included Morgan Stanley (1.07Mn), MPM BioImpact LLC (1.07Mn), ADAR1 Capital Management, LLC (843.85K), JANE STREET GROUP, LLC (333.82K), SPHERA FUNDS MANAGEMENT LTD. (159.75K).
• According to Business Quant data, leading holders of CRVS for March 2026 are ORBIMED ADVISORS LLC (7.17Mn), BlackRock, Inc. (6.16Mn), State Street Corp (3.57Mn), ADAMS STREET PARTNERS LLC (3.28Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.23Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.92Mn), Vivo Capital, LLC (2.81Mn), Morgan Stanley (2.5Mn), Deep Track Capital, LP (2.49Mn), WELLINGTON MANAGEMENT GROUP LLP (2.32Mn).